ClinicalTrials.gg
CompletedNCT03554005Updated Jul 15, 2019Results posted

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

A Phase 1 interventional study of PEG Interferon Alfa-2b and Acetaminophen in Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-07-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 20 years 5 months after the study started (first participant enrolled Dec 1997, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study is an extension study to base study protocol C/I97-188 (MK-4031-006). Its primary purpose is to assess the safety and tolerability of extended administration of polyethylene glycol (PEG) interferon alfa-2b in participants with solid tumors.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 29 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had a response of stable disease or better in PEG interferon alfa-2b base study C/I97-188 (MK-4031-006).
  • Has a Performance Status of 0 (normal activity), 1 (symptoms, but fully ambulatory), or 2 (symptomatic, but in bed \<50% of the day).
  • Is enrolled within two weeks of completing their last dose of PEG Interferon alfa-2b on the previous study and has not have received any other therapy during this period.

Exclusion criteria

Exclusion Criteria:

  • Discontinued prior to completing PEG interferon alfa-2b base study C/I97-188 (MK-4031-006).
  • Is pregnant or nursing.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)

    Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.

    Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen

  • Experimental
    PEG Interferon Alfa-2b 1.5 mcg/kg OW

    Participants receive PEG interferon alfa-2b 1.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.

    Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen

  • Experimental
    PEG Interferon Alfa-2b 3 mcg/kg OW

    Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.

    Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen

  • Experimental
    PEG Interferon Alfa-2b 4.5 mcg/kg OW

    Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.

    Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen

  • Experimental
    PEG Interferon Alfa-2b 6 mcg/kg OW

    Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.

    Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen

  • Experimental
    PEG Interferon Alfa-2b 7.5 mcg/kg OW

    Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.

    Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen

Interventions

  • Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.

    Also known as: MK-4031, SCH 54031, PEG Intron®

  • Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.

    Also known as: Tylenol®

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 42 Weeks

  2. Number of Participants Who Discontinued Treatment Due to an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 40 Weeks

Secondary outcomes

  1. Best Objective Response

    Best Objective Response data were based on World Health Organization (WHO) criteria and included four categories. Complete Response (CR) was the disappearance of all clinically detectable malignant disease. Partial Response (PR) was a decrease of ≥50% of the sum of products of largest perpendicular diameters of all bidimensionally measurable lesions; and a decrease of ≥50% in sum of largest diameters of all unidimensionally measure lesions. Stable Disease (SD) was a \<50% decrease or \<25% increase in sum of products of largest perpendicular diameters of all bidimensionally measurable lesions; or a \<50% decrease or \<25% increase in sum of diameters of all unidimensionally measurable lesions. In addition, no new lesions appeared. Progressive Disease (PD) was a ≥25% increase in size of at least one bidimensionally or unidimensionally measurable lesion or appearance of new lesion. Occurrence of pleural effusion or ascites was also considered PD if substantiated by positive cytology.

    Time frame: Up to 40 Weeks

07

Results

Posted Jul 15, 2019
Limitations and caveats
Adverse Event (AE) Preferred Terms were converted from WHO-ART dictionary to the MedDRA version 10.0.

Participant flow

Participant flow — Overall Study
MilestonePEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)PEG Interferon Alfa-2b 1.5 mcg/kg OWPEG Interferon Alfa-2b 3 mcg/kg OWPEG Interferon Alfa-2b 4.5 mcg/kg OWPEG Interferon Alfa-2b 6 mcg/kg OWPEG Interferon Alfa-2b 7.5 mcg/kg OW
Started12221111
Completed011150
Not completed1111611
Withdrew: Not in participant's best interest000001
Withdrew: Disease progression111156
Withdrew: Adverse event000003
Withdrew: Physician decision000010
Withdrew: Other000001

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 42 Weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event
ParticipantsPEG Interferon Alfa-2b 0.75 mcg/kg OWPEG Interferon Alfa-2b 1.5 mcg/kg OWPEG Interferon Alfa-2b 3 mcg/kg OWPEG Interferon Alfa-2b 4.5 mcg/kg OWPEG Interferon Alfa-2b 6 mcg/kg OWPEG Interferon Alfa-2b 7.5 mcg/kg OW
Number of Participants Who Experienced an Adverse Event12121111
PrimaryNumber of Participants Who Discontinued Treatment Due to an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 40 Weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Treatment Due to an Adverse Event
ParticipantsPEG Interferon Alfa-2b 0.75 mcg/kg OWPEG Interferon Alfa-2b 1.5 mcg/kg OWPEG Interferon Alfa-2b 3 mcg/kg OWPEG Interferon Alfa-2b 4.5 mcg/kg OWPEG Interferon Alfa-2b 6 mcg/kg OWPEG Interferon Alfa-2b 7.5 mcg/kg OW
Number of Participants Who Discontinued Treatment Due to an Adverse Event000003
SecondaryBest Objective Response

Best Objective Response data were based on World Health Organization (WHO) criteria and included four categories. Complete Response (CR) was the disappearance of all clinically detectable malignant disease. Partial Response (PR) was a decrease of ≥50% of the sum of products of largest perpendicular diameters of all bidimensionally measurable lesions; and a decrease of ≥50% in sum of largest diameters of all unidimensionally measure lesions. Stable Disease (SD) was a \<50% decrease or \<25% increase in sum of products of largest perpendicular diameters of all bidimensionally measurable lesions; or a \<50% decrease or \<25% increase in sum of diameters of all unidimensionally measurable lesions. In addition, no new lesions appeared. Progressive Disease (PD) was a ≥25% increase in size of at least one bidimensionally or unidimensionally measurable lesion or appearance of new lesion. Occurrence of pleural effusion or ascites was also considered PD if substantiated by positive cytology.

Time frame:
Up to 40 Weeks
Reported as:
Count of participants · Participants
Best Objective Response
ParticipantsPEG Interferon Alfa-2b 0.75 mcg/kg OWPEG Interferon Alfa-2b 1.5 mcg/kg OWPEG Interferon Alfa-2b 3 mcg/kg OWPEG Interferon Alfa-2b 4.5 mcg/kg OWPEG Interferon Alfa-2b 6 mcg/kg OWPEG Interferon Alfa-2b 7.5 mcg/kg OW
Complete Response (CR)001030
Partial Response (PR)000104
Stable Disease (SD)120064
Progressive Disease (PD)000112
Not Evaluated001011

Adverse events

Collected over Up to 42 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG Interferon Alfa-2b 0.75 mcg/kg OW0/1 (0%)0/1 (0%)1/1 (100%)
PEG Interferon Alfa-2b 1.5 mcg/kg OW0/2 (0%)1/2 (50%)2/2 (100%)
PEG Interferon Alfa-2b 3 mcg/kg OW0/2 (0%)0/2 (0%)1/2 (50%)
PEG Interferon Alfa-2b 4.5 mcg/kg OW0/2 (0%)0/2 (0%)2/2 (100%)
PEG Interferon Alfa-2b 6 mcg/kg OW1/11 (9.1%)1/11 (9.1%)11/11 (100%)
PEG Interferon Alfa-2b 7.5 mcg/kg OW0/11 (0%)3/11 (27.3%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventPEG Interferon Alfa-2b 0.75 mcg/kg OWPEG Interferon Alfa-2b 1.5 mcg/kg OWPEG Interferon Alfa-2b 3 mcg/kg OWPEG Interferon Alfa-2b 4.5 mcg/kg OWPEG Interferon Alfa-2b 6 mcg/kg OWPEG Interferon Alfa-2b 7.5 mcg/kg OW
ASTHENIAGeneral disorders0/11/20/20/20/110/11
PAINGeneral disorders0/11/20/20/20/110/11
CONFUSIONAL STATEPsychiatric disorders0/11/20/20/20/110/11
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/10/20/20/20/111/11
PYREXIAGeneral disorders0/10/20/20/20/111/11
PNEUMONIAInfections and infestations0/10/20/20/20/111/11
ARTHRALGIAMusculoskeletal and connective tissue disorders0/10/20/20/20/111/11
JOINT SWELLINGMusculoskeletal and connective tissue disorders0/10/20/20/20/111/11
CONVULSIONNervous system disorders0/10/20/20/21/110/11
SYNCOPENervous system disorders0/10/20/20/21/110/11
Most frequent other events
Showing 10 of 108
Most frequent other events
EventPEG Interferon Alfa-2b 0.75 mcg/kg OWPEG Interferon Alfa-2b 1.5 mcg/kg OWPEG Interferon Alfa-2b 3 mcg/kg OWPEG Interferon Alfa-2b 4.5 mcg/kg OWPEG Interferon Alfa-2b 6 mcg/kg OWPEG Interferon Alfa-2b 7.5 mcg/kg OW
ABDOMINAL PAINGastrointestinal disorders1/10/20/20/22/112/11
ASCITESGastrointestinal disorders1/10/20/20/20/110/11
DIARRHOEAGastrointestinal disorders1/11/20/20/23/112/11
NAUSEAGastrointestinal disorders0/12/20/20/22/114/11
CHILLSGeneral disorders0/12/21/21/21/111/11
FATIGUEGeneral disorders0/12/20/21/26/113/11
OEDEMA PERIPHERALGeneral disorders1/10/20/20/20/111/11
PYREXIAGeneral disorders0/12/20/21/20/113/11
ANOREXIAMetabolism and nutrition disorders1/11/20/20/22/110/11
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders1/10/20/20/20/111/11

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PEG Interferon Alfa-2b 0.75 mcg/kg OWPEG Interferon Alfa-2b 1.5 mcg/kg OWPEG Interferon Alfa-2b 3 mcg/kg OWPEG Interferon Alfa-2b 4.5 mcg/kg OWPEG Interferon Alfa-2b 6 mcg/kg OWPEG Interferon Alfa-2b 7.5 mcg/kg OWTotal
Mean62.0 ± NA51.5 ± 14.852 ± 0.059.5 ± 10.655.4 ± 9.655.8 ± 10.755.6 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)PEG Interferon Alfa-2b 0.75 mcg/kg OWPEG Interferon Alfa-2b 1.5 mcg/kg OWPEG Interferon Alfa-2b 3 mcg/kg OWPEG Interferon Alfa-2b 4.5 mcg/kg OWPEG Interferon Alfa-2b 6 mcg/kg OWPEG Interferon Alfa-2b 7.5 mcg/kg OWTotal
Female1101317
Male012181022
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 1997 to primary completion in Mar 2001, 38 months.

Results were first posted in Jul 2019, 18 years 3 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 38 months is close to that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2018
First posted
Jun 12, 2018
StartActual
Dec 29, 1997
Primary completionActual
Mar 16, 2001
CompletionActual
Mar 16, 2001
Results first posted
Jul 15, 2019
Last update
Jul 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03554005
Responsible party
Sponsor
First posted
Jun 12, 2018
Start date
Dec 29, 1997
Primary completion
Mar 16, 2001
Completion
Mar 16, 2001
Results posted
Jul 15, 2019
Last update
Jul 15, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion